Suppr超能文献

COVID-19 患者风湿性疾病的临床结局:全球数据的系统评价和荟萃分析。

Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data.

机构信息

Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore.

Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China.

出版信息

Autoimmun Rev. 2021 Apr;20(4):102778. doi: 10.1016/j.autrev.2021.102778. Epub 2021 Feb 18.

Abstract

OBJECTIVES

The impact of rheumatic diseases on COVID-19 infection remains poorly investigated. Here we performed a systematic review and meta-analysis to evaluate the outcomes of COVID-19 in patients with rheumatic diseases.

METHODS

We systematically searched PubMed, Embase, Cochrane Library, Scopus and preprint database up to 29th August 2020, for publications with confirmed COVID-19 infection in patients with rheumatic diseases. The primary outcomes were the rates of hospitalization, oxygen support, intensive care unit (ICU) admission and death. A meta-analysis of effect sizes using the random-effects models was performed, and meta-regression analyses were performed to explore heterogeneity. The data from the COVID-19 Global Rheumatology Alliance physician registry (the COVID-19 GRA) was used as a reference.

RESULTS

A total of 31 articles involving 1138 patients were included in this systematic review and meta-analysis. The publications were from Europe, Asia and North America, but none from other continents. The overall rates of hospitalization, oxygen support, ICU admission and fatality among COVID-19 infected patients with rheumatic diseases were 0.58 (95% confidence interval (CI) 0.48-0.67), 0.33 (95% CI 0.21-0.47), 0.09 (95% CI 0.05-0.15) and 0.07 (95% CI 0.03-0.11), respectively. The rate of oxygen support in Europe (0.48, 95% CI 0.4-0.57) was higher than that in other continents. Among all hospitalized patients, the rates of oxygen support, ICU admission and fatality were 0.61 (95% CI 0.48-0.73), 0.13 (95% CI 0.07-0.21) and 0.13 (95% CI 0.09-0.18), respectively. The fatality rate was highest in Europe (0.19, 95% CI 0.15-0.24). The fatality rate was higher both in this meta-analysis and the COVID-19 GRA (7.0% and 6.7%, respectively) than that (3.4%) in WHO database, although the age, gender and comorbidity were not matched.

CONCLUSION

Patients with rheumatic diseases remain vulnerable with substantial rates of severe outcomes and a geographic variation. More studies were urgently needed to elucidate the risk factors of severe outcomes in this population.

摘要

目的

风湿性疾病对 COVID-19 感染的影响仍研究不足。在此,我们进行了一项系统评价和荟萃分析,以评估风湿性疾病患者 COVID-19 的结局。

方法

我们系统地检索了 PubMed、Embase、Cochrane 图书馆、Scopus 和预印本数据库,截至 2020 年 8 月 29 日,以获取风湿性疾病患者确诊 COVID-19 感染的出版物。主要结局指标为住院、吸氧支持、重症监护病房(ICU)入院和死亡的发生率。使用随机效应模型对效应大小进行荟萃分析,并进行荟萃回归分析以探索异质性。使用 COVID-19 全球风湿病联盟医生登记处(COVID-19 GRA)的数据作为参考。

结果

本系统评价和荟萃分析共纳入 31 篇文章,涉及 1138 例患者。这些出版物来自欧洲、亚洲和北美,但没有来自其他大陆的。COVID-19 感染的风湿性疾病患者住院、吸氧支持、ICU 入院和死亡的总体发生率分别为 0.58(95%置信区间(CI)0.48-0.67)、0.33(95%CI 0.21-0.47)、0.09(95%CI 0.05-0.15)和 0.07(95%CI 0.03-0.11)。欧洲吸氧支持率(0.48,95%CI 0.4-0.57)高于其他大陆。在所有住院患者中,吸氧支持、ICU 入院和死亡的发生率分别为 0.61(95%CI 0.48-0.73)、0.13(95%CI 0.07-0.21)和 0.13(95%CI 0.09-0.18)。欧洲的死亡率最高(0.19,95%CI 0.15-0.24)。本荟萃分析和 COVID-19 GRA 的死亡率(分别为 7.0%和 6.7%)均高于世卫组织数据库(3.4%),尽管年龄、性别和合并症未匹配。

结论

风湿性疾病患者仍然脆弱,严重结局发生率高且存在地域差异。迫切需要更多的研究来阐明该人群发生严重结局的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f311/7889462/2996e1ef4bcb/gr1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验